Newsroom
New milestone reached as our potential new child-friendly treatment option for schistosomiasis is validated by EMA
The Pediatric Praziquantel Consortium is pleased to announce that the European Medicines Agency (EMA) has validated for review the application for our potential new treatment option for schistosomiasis in preschool-aged children (3 months to 6 years of age).
Millions of preschool-aged children affected by schistosomiasis are not receiving treatment due to the lack of a suitable medication. With this validation, a key milestone has been reached in the ongoing effort to eliminate this neglected tropical disease that affects more than 200 million people worldwide, including at least 50 million preschool-aged children.
Read our full press release1
The press release is also available in Japanese, Brazilian Portuguese, and French.
____